Biological therapy safety in chronic inflammatory arthropathy patients
| Autor: | Noemi Martínez-López-de-Castro, Guadalupe Piñeiro-Corrales, Alicia Martín-Vila, Francisco José Maceiras-Pan, Miriam Álvarez-Payero, Marisol Samartín-Ucha, José M. Pego-Reigosa, Maria Rodriguez-Rodriguez, Rafael Benito Melero-González |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty Heart disease Inflammatory arthritis 030204 cardiovascular system & hematology Patient safety Psoriatic arthritis 03 medical and health sciences 0302 clinical medicine Internal medicine Computer software medicine Repolarization In patient Adverse effect skin and connective tissue diseases Prospective cohort study Qt variability 030203 arthritis & rheumatology Ankylosing spondylitis integumentary system business.industry Significant difference medicine.disease Increased risk Rheumatoid arthritis Cohort Cardiology Original Article lcsh:RC581-607 business Cohort study |
| Zdroj: | Eur J Rheumatol European Journal of Rheumatology, Vol 7, Iss 2, Pp 53-59 (2020) |
| ISSN: | 2147-9720 |
| Popis: | OBJECTIVE: The marketing of biological therapies transformed the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. But there is still concern about patient safety and management in daily clinical practice. The aim of this study was to estimate risk factors of the adverse effects in a cohort of Spanish patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. METHODS: A single institution, descriptive, retrospective, cohort study was developed from January 2009 to December 2016. Patients diagnosed with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis on biological therapies were included. Undesirable events affecting patients during biological therapy, their clinical implications and the use of health resources related to adverse effects were collected. RESULTS: Three hundred and sixty-two patients corresponding to 478 biological therapy lines were analysed. It implied 1192 years of monitoring. There were 57 adverse effects per 100 biological patient-years and 4.8 serious adverse effects per 100 biological patient-years. The only significant factor for a likely serious adverse effect was having a Charlson Index ≥10, OR of 6.2 (CI 95%: 3.4–11.1, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|